Liposomal Coenzyme Q10

Liposomal Coenzyme Q10 是一种通过脂质体纳米载体包裹脂溶性辅酶 Q10 (CoQ10) (MS-F73035) 的口服有效递送系统,可减轻肝脏氧化应激、缓解肝脏炎症反应、减少肝细胞凋亡 (apoptosis) 并改善肝纤维化,同时可激活铁死亡抑制蛋白 1 (FSP1)/辅酶 Q10 系统,减少丙二醛和 ROS 的积累并抑制神经元铁死亡 (ferroptosis),可用于丙酸 (Propanoic acid) (MS-K59357) 诱导的肝损伤和蛛网膜下腔出血的相关研究。
Liposomal Coenzyme Q10
产品编号: MS-Q00106 纯度: 98%
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1g
询价
3-5 天
5g
询价
3-5 天
10g
询价
3-5 天
50g
询价
询价

产品描述

Liposomal Coenzyme Q10 是一种通过脂质体纳米载体包裹脂溶性辅酶 Q10 (CoQ10) (MS-F73035) 的口服有效递送系统,可减轻肝脏氧化应激、缓解肝脏炎症反应、减少肝细胞凋亡 (apoptosis) 并改善肝纤维化,同时可激活铁死亡抑制蛋白 1 (FSP1)/辅酶 Q10 系统,减少丙二醛和 ROS 的积累并抑制神经元铁死亡 (ferroptosis),可用于丙酸 (Propanoic acid) (MS-K59357) 诱导的肝损伤和蛛网膜下腔出血的相关研究。

生物实验数据

生物活性 Liposomal Coenzyme Q10 is an orally effective delivery system that encapsulates liposoluble coenzyme Q10 (CoQ10) (MS-F73035) via liposomal nanocarriers, and it can alleviate hepatic oxidative stress, mitigate hepatic inflammatory responses, reduce hepatocyte apoptosis (apoptosis), and improve liver fibrosis, while also activating the ferroptosis suppressor protein 1 (FSP1)/coenzyme Q10 system, reducing the accumulation of malondialdehyde and ROS, and inhibiting neuronal ferroptosis (ferroptosis), and it can be used for research related to Propanoic acid (Propanoic acid) (MS-K59357)-induced liver injury and subarachnoid hemorrhage.
体外研究
(In Vitro)

Liposomal coenzyme Q10 (10 μM 等效 CoQ10) 可激活 FSP1、减轻铁过载、抑制氧化应激并缓解 Hb 刺激的 N2A 神经元细胞铁死亡,其作用效力弱于神经元靶向性脂质体辅酶 Q10 (CoQ10-Tet1-Lipos)。

体内研究
(In Vivo)

Liposomal Coenzyme Q10 (10 mg/kg/天;口服;每日给药;连续 5 天) 可通过减轻氧化应激、炎症、细胞凋亡和纤维化来缓解丙酸诱导的肝损伤,并改善肝脏组织学结构。
Liposomal Coenzyme Q10 (100 mg/kg;静脉注射;每日 1 次;连续 3 天) 可激活 FSP1/CoQ10 系统、抑制神经元铁死亡,并相较于溶媒组和非靶向脂质体组改善蛛网膜下腔出血 (SAH) 模型小鼠的神经功能,但其效果弱于神经元靶向的 CoQ10-Tet1-Lipos。

Animal Model: Albino rats (adult male, 150-170 g, propionic acid-induced liver injury)
Dosage: 10 mg/kg/day; 100 mg/kg/day (acetyl-L-carnitine, combination group)
Administration: p.o.; daily; 5 days (administered one hour after propionic acid)
Result: Marked reduction in serum AST, ALT, and LDH activity levels compared to the propionic acid-only group.
Significant reduction in hepatic malondialdehyde (MDA) levels, and significant restoration of hepatic reduced glutathione (GSH) levels and superoxide dismutase (SOD) enzyme activity compared to the propionic acid-only group.
Significant downregulation of hepatic proinflammatory cytokines IL-6 and TNF-α levels compared to the propionic acid-only group.
Significant reduction in hepatic caspase-3 levels, and significant downregulation of hepatic cytokeratin-18 (CK18) mRNA expression compared to the propionic acid-only group.
Significant downregulation of hepatic transforming growth factor-beta1 (TGF-β1) and SMAD3 protein expression compared to the propionic acid-only group.
Significant downregulation of hepatic high-mobility group box-1 (HMGB1) mRNA expression compared to the propionic acid-only group.
Showed intact lobular hepatic architecture, with hepatocytes arranged in thin plates and only mild hydropic degeneration, compared to the propionic acid-only group which exhibited intracytoplasmic vacuoles, congested/dilated sinusoids, and necrotic areas; combination group showed almost normal hepatic structure and architecture.
Animal Model: C57BL/6 (male, 6-8 weeks old, 20-25 g, intracranial vessel puncture via external carotid artery insertion of a monofilament)
Dosage: 100 mg/kg
Administration: i.v.; daily; 3 days
Result: Increased FSP1 levels at the lesion site relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Reduced lesion-site iron content relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Reduced lesion-site MDA concentration relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Reduced oxidative stress (measured via 8-OHdG fluorescence intensity) relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Increased the number of morphologically normal neurons at the lesion site relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Inhibited neuronal ferroptosis (preserved mitochondrial morphology via TEM) relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group.
Produced shorter latency to find the platform and longer time spent in the correct quadrant in the Morris water maze test relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos groups, indicating improved spatial memory.
Achieved a higher modified Garcia score relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group, indicating improved sensory and motor function.
Resulted in shorter time to reach the 20 cm mark in the chimney behavioral test relative to SAH-only, Lipos, and Tet1-Lipos groups, though to a lesser extent than the CoQ10-Tet1-Lipos group, indicating improved motor function.
Had a mortality rate of 15.63% (10/64) in behavioral test groups and 17.24% (5/29) in tissue collection groups, comparable to other SAH treatment groups.
性状 粉末
颜色 Yellow to orange

化学信息

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础